Chimeric Therapeutics is trading approximately 13.16% up today at A$0.04. - The significant upward movement follows positive interim results from its Phase 1/2 CHM CDH17 clinical trial on July 23, reporting early tumor shrinkage in patients. - Additionally, the company recently announced the conversion of convertible notes into ordinary shares on July 22, increasing its total quoted capital. - This price action indicates strong investor response to recent company-specific developments.